HURA
TuHURA Biosciences Inc
$
3.890
- Overview
- Forecast
- Valuation
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.110
Open
4.070
VWAP
3.96
Vol
85.78K
Mkt Cap
169.92M
Low
3.840
Amount
339.64K
EV/EBITDA(TTM)
--
Total Shares
43.68M
EV
166.71M
EV/OCF(TTM)
--
P/S(TTM)
--
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. In addition, the Company is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting myeloid derived suppressor cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Its IFx platform technology utilizes a proprietary plasmid DNA (pDNA) or messenger RNA (mRNA).
Show More
2 Analyst Rating
247.04% Upside
Wall Street analysts forecast HURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HURA is 13.50 USD with a low forecast of 12.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
247.04% Upside
Current: 3.890
Low
12.00
Averages
13.50
High
15.00
247.04% Upside
Current: 3.890
Low
12.00
Averages
13.50
High
15.00
HC Wainwright & Co.
Robert Burns
Strong Buy
Maintains
$13 → $12
2025-04-03
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$13 → $12
2025-04-03
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Initiates
$13
2025-03-03
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$13
2025-03-03
Initiates
Strong Buy
Reason
Rodman & Renshaw
Tony Butler
Strong Buy
Initiates
$11
2024-12-19
Reason
Rodman & Renshaw
Tony Butler
Price Target
$11
2024-12-19
Initiates
Strong Buy
Reason
Rodman & Renshaw initiated coverage of TuHURA Biosciences with a Buy rating and $11 price target. TuHURA is focused on developing treatments to overcome primary and acquired resistance to checkpoint inhibitors by using its proprietary technology platform, Immune FxTM, the analyst tells investors in a research note. The firm says the company's strategy leverages bacterial proteins to activate the immune system avoids common issues like the toxicity and infections often linked to using attenuated bacteria for cancer therapy.
See All Ratings
Valuation Metrics
The current forward P/E ratio for TuHURA Biosciences Inc (HURA.O) is -9.65, compared to its 5-year average forward P/E of -9.37. For a more detailed relative valuation and DCF analysis to assess TuHURA Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-9.37
Current PE
-9.65
Overvalued PE
-6.01
Undervalued PE
-12.73
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2024Q4
YoY :
+359.33%
-15.38M
Operating Profit
FY2024Q4
YoY :
+485.35%
-19.52M
Net Income after Tax
FY2024Q4
YoY :
-98.41%
-1.10
EPS - Diluted
FY2024Q4
YoY :
+755.24%
-12.90M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
206.0K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
16.0K
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
HURA News & Events
Events Timeline
2025-05-05 (ET)
2025-05-05
08:08:55
TuHURA Biosciences initiates Phase 1b/2a study of IFx-Hu2.0 in carcinoma
2025-04-28 (ET)
2025-04-28
08:11:56
TuHURA Biosciences and Kineta present updated results of cancer candidates
2024-11-25 (ET)
2024-11-25
07:47:04
TuHURA Biosciences sees cash runway into 2H25
Sign Up For More Events
Sign Up For More Events
News
1.0
05-13PRnewswireTuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference
9.0
05-05PRnewswireTuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)
9.0
04-28PRnewswireTuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
Sign Up For More News
People Also Watch
SWKH
SWK Holdings Corp
13.650
USD
0.00%
SLRN
ACELYRIN Inc
2.045
USD
-2.15%
BCOV
Brightcove Inc
4.450
USD
0.00%
WRN
Western Copper and Gold Corp
1.070
USD
-6.14%
BVFL
BV Financial Inc
15.850
USD
+0.38%
OBIO
Orchestra Biomed Holdings Inc
2.820
USD
-4.08%
FTEL
Fitell Corp
0.500
USD
-0.20%
CGEN
Compugen Ltd
1.310
USD
-2.96%
KNOP
Knot Offshore Partners LP
6.620
USD
-0.30%
MBCN
Middlefield Banc Corp
29.030
USD
-3.17%
FAQ
What is TuHURA Biosciences Inc (HURA) stock price today?
The current price of HURA is 3.89 USD — it has decreased -5.12 % in the last trading day.
What is TuHURA Biosciences Inc (HURA)'s business?
What is the price predicton of HURA Stock?
What is TuHURA Biosciences Inc (HURA)'s revenue for the last quarter?
What is TuHURA Biosciences Inc (HURA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for TuHURA Biosciences Inc (HURA)'s fundamentals?
How many employees does TuHURA Biosciences Inc (HURA). have?